After a recent surprise sale of its North American subsidiaries amid the prolonged pandemic, South Korea's GC Pharma is prioritizing its focus on development and commercialization of a plasma therapy for COVID-19, while awaiting multiple drug approvals in overseas markets.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?